Search Within

Nicole Lamanna

Formats
  1. Meeting Abstract (39)
  2. Journal Article (19)
  3. Book Section (2)
Groups
  1. Center for Hematologic Malignancies (35)
  2. Department of Medicine (35)
  3. Hematologic Malignancies, Division of (35)
  4. Adult Leukemia (23)
  5. GSK Faculty (19)
  6. Hematologic Malignancies Research (19)

More Groups

People
  1. Mark Weiss (24)
  2. Peter Maslak (18)
  3. Joseph Jurcic (17)
  4. David Scheinberg (13)
  5. Mark Heaney (12)
  6. Renier Brentjens (12)

More People

Years
  1. 2015 (1)
  2. 2014 (7)
  3. 2013 (7)
  4. 2012 (9)
  5. 2011 (4)
  6. 2010 (2)

More Years

Publications
  1. Blood (19)
  2. Journal of Clinical Oncology (15)
  3. Current Hematologic Malignancy Reports (5)
  4. Current Oncology Reports (2)
  5. Haematologica (2)
  6. Advances in Pharmacology (1)

More Publications

Publishers
  1. American Society of Hematology (19)
  2. American Society of Clinical Oncology (15)
  3. Springer (7)
  4. American Association for Cancer Research (2)
  5. CMP Healthcare Media (2)
  6. Elsevier Inc. (2)

More Publishers

Results (60)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • High leveI T cell suppression following purine analog therapy for patients with CLL correlates with important clinical benefit
    Meeting Abstract

    Landau, H.; Lamanna, N.; Hobart, S.; Weiss, M. A.
    Blood (2006)

    Fulltext@MSK | Save
  • In adult ALL, less is now more
    Journal Article

    Weiss, M. A.; Lamanna, N.
    Blood (2006)

    Fulltext@MSK | Save
  • Clinical manifestations and treatment of newly diagnosed acute lymphoblastic leukemia in adults
    Journal Article

    Landau, H.; Lamanna, N.
    Current Hematologic Malignancy Reports (2006)

    Fulltext@MSK | Save
  • Purine analogue-based chemotherapy regimens for second-line therapy in patients with chronic lymphocytic leukemia
    Journal Article

    Lamanna, N.; Weiss, M. A.
    Seminars in Hematology (2006)

    Fulltext@MSK | Save
  • Pentostatin, cyclophosphamide, and rituximab is an active, well-tolerated regimen for patients with previously treated chronic lymphocytic leukemia
    Journal Article

    Lamanna, N.; Kalaycio, M.; Maslak, P.; Jurcic, J. G.; Heaney, M.; Brentjens, R.; Zelenetz, A. D.; Horgan, D.; Gencarelli, A.; Panageas, K. S.; more...
    Journal of Clinical Oncology (2006)

    Fulltext@MSK | Save
  • Advances in the treatment of chronic lymphocytic leukemia
    Journal Article

    Lamanna, N.
    Current Hematologic Malignancy Reports (2006)

    Fulltext@MSK | Save
  • Combination chemotherapy regimens with pentostatin in patients with chronic lymphocytic leukemia and other low grade lymphoid neoplasms
    Meeting Abstract

    Weiss, M. A.; Kalaycio, M.; Zelenetz, A. D.; Lamanna, N.
    Annals of Oncology (2005)

    Fulltext@MSK | Save
  • A randomized trial of cytarabine with high-dose mitoxantrone compared to a standard vincristine/prednisone-based regimen as induction therapy for adult patients with ALL
    Meeting Abstract

    Weiss, M. A.; Heffner, L.; Lamanna, N.; Kalaycio, M.; Schiller, G.; Coutre, S.; Maslak, P.; Jurcic, J.; Panageas, K.; Scheinberg, D. A.
    Journal of Clinical Oncology (2005)

    Fulltext@MSK | Save
  • Pentostatin, cyclophosphamide, and rituximab (PCR) has comparable activity but appears to be better tolerated than fludarabine, cyclophosphamide, and rituximab (FCR) in patients with previously treated chronic lymphocytic leukemia
    Meeting Abstract

    Lamanna, N.; Kalaycio, M.; Maslak, P.; Heaney, M. L.; Brentjens, R.; Jurcic, J.; Biederman, E.; Gencarelli, A. N.; Panageas, K. S.; Scheinberg, D. A.; more...
    Blood (2005)

    Fulltext@MSK | Save
  • Advances in the treatment of chronic lymphocytic leukemia
    Journal Article

    Lamanna, N.
    Current Oncology Reports (2005)

    Fulltext@MSK | Save